Clinical Trial Update: Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating office-sclerotherapy for epistaxis in patients with hereditary hemorrhagic telangiectasia; results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epistaxis
• Hereditary Hemorrhagic Telangiectasia

Snippet

Sponsor: University of Minnesota | Conditions: Epistaxis, Hereditary Hemorrhagic Telangiectasia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-04-20